BQ Prime’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BQ Prime’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
IDBI Capital Report
LTIMindtree Ltd. reported subdued Q1 FY24 revenues mainly led by slow decision making, delay in ramp ups, slowdown in discretionary spend and banking.
While the company continues to win robust deals ($1.4 billion, 1.3 times book to bill) there is delay in conversion and ramp up. This uncertainty prompt us to revise FY24E revenue estimates to 8% YoY versus 9% YoY earlier.
However, LTIMindtree is winning large deals, multi-year deals and will be key beneficiary of deal ramp ups and deal conversions in improving macro.
Hence we have kept our 15% YoY growth assumption for FY25E.
In addition, we expect 143 basis points margin improvements over FY23-FY25E. This will lead to revenue and profit compound annual growth rate of 12% and 15% over FY23-FY25E.
Considering the recent run up in price, we maintain our 'Hold' rating on the stock and target price of Rs 4,975 (25 times FY25E earnings per share).
Click on the attachment to read the full report:
DISCLAIMER
This report is authored by an external party. BQ Prime does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BQ Prime.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.
RECOMMENDED FOR YOU

IDBI Bank Takes Zee To Insolvency Court, Threatened With Defamation In Return


Japan PM Shigeru Ishiba To Step Down As Leadership Crisis Continues


US Tariffs’ Immediate Impact On Indian Exports “Limited”, But Risks Loom: FinMin


Lupin Q1 Review: Dolat Capital Maintains 'Add', But Cuts Target Price — Here's Why
